TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00268372
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00268372
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02847481
Drug: placebo fecal microbiota transplantation
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo fecal microbiota transplantation
Study: NCT04879498
Drug: Monolithic zirconia
Normalized name: zirconium
DrugBank: Aluminum zirconium trichlorohydrex gly (DB11116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To assess the clinical performance and survival of posterior monolithic zirconia fixed partial dentures
Study: NCT01282515
Drug: clobetasol propionate 0,05% ointment
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: continuously daily treatment for 6 weeks
Study: NCT01282515
Drug: hexaminolevulinate
Normalized name: Hexaminolevulinate
DrugBank: Hexaminolevulinate (DB06261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one PDT treatment
Study: NCT04633850
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone 8 mg. Given once at the end of surgery.
Study: NCT04633850
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine dose according to weight. \<60 kg: Total dose 100mg 60-90kg: Total dose 150mg \>90kg: Total dose 200mg~Given once at the end of surgery.
Study: NCT00561106
Drug: prednisone- valacyclovir
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisone, a dose of 1 mg/kg body weight was given daily for 7 days. The treatment was tapered over the next 14 days. Those taking valacyclovir received 1000 mg in two daily doses for 7 days.
Study: NCT00561106
Drug: prednisone-placebo
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisone, a dose of 1 mg/kg body weight was given daily for 7 days
Study: NCT03332784
Drug: TAK-925
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-925 Intravenous Infusion
Study: NCT00808002
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir 400 mg every 12 hours
Study: NCT00808002
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc 300 mg every 12 hours
Study: NCT00808002
Drug: Tenofovir/Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir/Emtricitabine 300/200 mg every 24 hours
Study: NCT00061425
Drug: radiolabeled epratuzumab
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03239327
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00098397
Drug: romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02909933
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02909933
Drug: metformin and liraglutide
Normalized name: Liraglutide
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00438841
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00438841
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00438841
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00661297
Drug: Levitra (Vardenafil, BAY38-9456)
Normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg Vardenafil to be taken 1 h prior to sexual attempt
Study: NCT03404544
Drug: Carbetocin bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Carbetocin (DB01282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin 100 mcg intravenous as a bolus (less than 2 sec)
Study: NCT03404544
Drug: Carbetocin infusion
Normalized name: Duo Fusion
DrugBank: Carbetocin (DB01282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin 100 mcg intravenous as a 10 minutes infusion
Study: NCT00040417
Drug: FLUDARABINE
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00040417
Drug: FK506
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00040417
Drug: G-SCF (Granulocyte-colony stimulating factor)
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00346853
Drug: 4-Methylpyrazole
Normalized name: 4-methylpyrazole
DrugBank: Fomepizole (DB01213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg/kg dose
Study: NCT04382846
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide
Study: NCT00000367
Drug: Treatment of depression
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01760798
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01376154
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00388804
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg By Mouth (PO) Daily
Study: NCT00388804
Drug: Leuprolide
Normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.5 mg Intramuscularly (IM) Every 3 Months or 7.5 mg IM Every 1 Month
Study: NCT00388804
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10.8 mg Subcutaneously Every 3 Months or 3.6 mg Subcutaneously Every 1 Month
Study: NCT00388804
Drug: Flutamide
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg by mouth three times daily on first 21-30 Days. May be used instead of Bicalutamide.
Study: NCT00938405
Drug: Colesevelam HCl
Normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
Study: NCT01035333
Drug: Orlistat
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg capsule three times a day for up to 6 months
Study: NCT00092092
Drug: Montelukast chewable tablets
Normalized name: montelukast Chewable Tablet
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium 5 mg chewable tablets
Study: NCT00092092
Drug: Budesonide inhaler
Normalized name: budesonide Inhalation Suspension
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 200 mcg inhalation powder
Study: NCT00092092
Drug: Placebo to montelukast chewable tablets
Normalized name: montelukast Chewable Tablet
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo chewable tablets
Study: NCT00092092
Drug: Placebo to budesonide inhaler
Normalized name: budesonide Inhalation Suspension
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo inhalation powder
Study: NCT02336451
Drug: Ceritinib
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: LDK378 is a gelatin capsule, administered orally once daily at a dose of 750 mg (five 150 mg capsules) on a continuous dosing schedule on an empty stomach.
Study: NCT04157933
Drug: 009-A1
Normalized name: Zygomycin A1
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled apomorphine via Staccato aerosol, Dose 1 (low dose) each day for first 5 days, then 3 doses Dose 1 (low dose) q 2 hr on Day 6
Study: NCT04157933
Drug: 009-A3
Normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled apomorphine via Staccato aerosol, Dose 3 (high dose) each day for first 5 days, then 3 doses Dose 3 (high dose) q 2 hr on Day 6
Study: NCT04157933
Drug: 009-B2 (placebo --> active) crossover
Normalized name: VITAMIN B2
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Up to 2 doses (placebo) ; minimum of 2 hrs between doses, on Day 1, followed by Up to 2 doses (Dose 3) ; minimum of 2 hrs between doses, on Day 2
Study: NCT05846698
Drug: tibolone
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg once daily
Study: NCT02132533
Drug: Nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine 20 mg orally, then nifedipine 20 mg orally after 90 minutes if still contracting. Continue nifedipine 20 mg orally every 4 hours after the first dose for 48 hours.
Study: NCT03277352
Drug: INCAGN01876
Normalized name: Incagn01876
DrugBank: Ragifilimab (DB18853)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Phase 1 subjects will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose and schedule according to cohort and treatment group enrollment. In Phase 2, subjects will be administered IV study drug at the recommended dose from Phase 1.
Study: NCT03277352
Drug: Epacadostat
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat will be self-administered orally at the protocol-defined dose.
Study: NCT03277352
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered IV at the protocol-defined dose.
Study: NCT02478645
Drug: ramosetron 0.3
DrugBank: Ramosetron (DB09290)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: The ramosetron 0.3 group receives ramosetron 0.3 mg at the end of surgery.
Study: NCT02478645
Drug: ramosetron 0.45
DrugBank: Ramosetron (DB09290)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: The ramosetron 0.45 group receives ramosetron 0.45 mg at the end of surgery.
Study: NCT02478645
Drug: ramosetron 0.6
DrugBank: Ramosetron (DB09290)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: The ramosetron 0.6 group receives ramosetron 0.6 mg at the end of surgery.
Study: NCT00707213
Drug: [18F]fluoro-2-deoxy-D-glucose (FDG)
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG-PET/CT scan-The scans that will be done with a radioactive sugar (\[18F\]fluoro-2-deoxy-D-glucose) and positron emission tomography (FDG-PET/CT). These scans will help to identify areas of possible infection.
Study: NCT00252213
Drug: Human BNP
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01026129
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
Study: NCT00034645
Drug: Posaconazole oral suspension
Normalized name: Posaconazole Oral Suspension
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02397447
Drug: Momordica charantia
Normalized name: MOMORDICA CHARANTIA STEM
DrugBank: Momordica charantia fruit (DB14265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momordica Charantia: 2000 mg per day for three months
Study: NCT00759122
Drug: venlafaxine (Effexor)
Normalized name: venlafaxine Oral Tablet [Effexor]
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching capsules containing venlafaxine 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
Study: NCT02531854
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Chemotherapy
Study: NCT00592046
Drug: ZIO-101 (Darinaparsin)
Normalized name: Zioptan
DrugBank: Tafluprost (DB08819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ZIO-101 (Darinaparsin) given for five consecutive days to be repeated every 28 days for up to six months. This is a dose escalation study.
Study: NCT00706784
Drug: Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System
Normalized name: ethinyl estradiol / segesterone acetate Vaginal System [Annovera]
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System
Study: NCT00040092
Drug: Virulizin®
DrugBank: Virulizin (DB17098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03941743
Drug: Fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT03941743
Drug: Fingolimod Hydrochloride
Normalized name: Fingolimod Hydrochloride
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00005973
Drug: BMS-214662
Normalized name: BMS-214662
DrugBank: BMS-214662 (DB12234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00004221
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00004221
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00004221
Drug: Topotecan Hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03209401
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: an oral PARP inhibitor
Study: NCT03209401
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a platinum-based injection
Study: NCT00269906
Drug: Abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04169191
Drug: Sildenafil Citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort 1 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, and subsequent doses of 2.5mg/kg/dose q12h (= 5 mg/kg/day from dose #2) Cohort 2 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, 3rd dose of 3mg/kg/dose, and subsequent doses of 3mg/kg/dose q12h (= 6 mg/kg/day from dose #3) dose expansion phase in up to 5-15 asphyxiated neonates
Study: NCT03423810
Drug: Hydralazine
Normalized name: Hydralazine
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be asked to take pills two times per day for 6 weeks. This is a dose increasing study with potential doses ranging from 5 mg two times per day to 50 mg two times per day.
Study: NCT01452568
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg/daily for three months, starting day after surgery
Study: NCT01452568
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin daily dosage to obtain an INR in between 2,0 to 3,0. Started the day after surgery and continued for three months.
Study: NCT04339712
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In case of diagnosis of MAS treatment with anakinra
Study: NCT04339712
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In case of diagnosis of immune dysregulation treatment with tocilizumab
Study: NCT01149122
Drug: Gemcitabine/Oxaliplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GEMOX: (Gemcitabine 100 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q (every) 2 weeks
Study: NCT01149122
Drug: Gemcitabine/Oxaliplatin with Erlotinib (Tarceva)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GEMOX + Tarceva: (Gemcitabine 1000 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q 2weeks; Tarceva 100 mg qd
Study: NCT02567851
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Monoclonal antibody drug conjugate
Study: NCT05614440
Drug: Local anesthetic + tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Using tramadol hydrochloride and articain HCL for inferior alveolar nerve block
Study: NCT03126071
Drug: Raltitrexed
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed:3mg/m2,iv 15min,d1,q3w.
Study: NCT03126071
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan:250mg/m2,iv 90min,d1,q3w.
Study: NCT03126071
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin:130mg/m2,iv 120min,d1,q3w.
Study: NCT03126071
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab:75mg/kg,iv 30min,d1,q3w.
Study: NCT03715777
Drug: Clostridium botulinum type A (BoNTA)
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder and solution for solution for injection Specify total dose: 80 U~Route of administration:
Study: NCT02459080
Drug: TD-4208
Normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01439867
Drug: Cinacalcet hydrochloride
Normalized name: Cinacalcet Hydrochloride
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cinacalcet was provided as 5 mg capsules that were opened, and the contents were either sprinkled on soft food or suspended into a sucrose syrup to create a liquid suspension for administration. All doses were administered with food or shortly after a meal at the same time daily.
Study: NCT00064649
Drug: Finasteride and Alfuzosin
Normalized name: finasteride and tadalafil
DrugBank: Alfuzosin (DB00346)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg
Study: NCT01511263
Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG
Normalized name: Neova Complex HQ Plus
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.~EGCG, 675 mg/day, oral, for one year.
Study: NCT03148522
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: receive escitalopram
Study: NCT03148522
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: receive duloxetine
Study: NCT03148522
Drug: Mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: receive mirtazapine
Study: NCT01798875
Drug: oral metformin
Normalized name: metformin Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01798875
Drug: oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01131104
Drug: PDE5 Inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observational study of participants who have been prescribed phosphodiesterase type 5 (PDE5) inhibitors by their physician during routine clinical practice.
Study: NCT00790400
Drug: Everolimus (RAD001)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus is used in 5 mg strength tablets, blister-packed under aluminum foil in units of ten tablets and dosed on a daily basis. 10mg daily dosing throughout the trial.
Study: NCT00790400
Drug: Everolimus Placebo
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Matching placebo was provided as a matching tablet and was also blister-packed under aluminum foil in units of ten.
Study: NCT05034406
Drug: 2% Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 mL of 2% lidocaine injected at the trocar insertion site.
Study: NCT05034406
Drug: 0.5% levobupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 mL of 0.5% levobupivacaine injected at the trocar insertion site.
Study: NCT03149575
Drug: VAL-083, Dianhydrogalactitol
DrugBank: Dianhydrogalactitol (DB12873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAL-083 given by intravenous infusion at a dose 40 mg/m2 IV on days 1, 2, and 3 of a 21-day treatment-cycle, for up to 12, 21-day treatment cycles
Study: NCT03149575
Drug: Physician's Choice of Salvage Therapy - temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The product label for temozolomide (Temodar®) provides the following dosing information.~Newly Diagnosed GBM: 75 mg/m2 for 42 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m2 once daily for Days 1-5 of a 28-day cycle of Temodar® for 6 cycles.~Refractory Anaplastic Astrocytoma: Initial dose 150 mg/m2 once daily for 5 consecutive days per 28-day treatment cycle.
Study: NCT03149575
Drug: Physician's Choice of Salvage Therapy - lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The product label for lomustine (CeeNu; lomustine; CCNU) provides the following dosing information.~The recommended dose of lomustine in adult and pediatric patients as a single agent in previously untreated patients is 130 mg/m2 as a single oral dose every 6 weeks In individuals with compromised bone marrow function, the dose should be reduced to 100 mg/m2 every 6 weeks.